12tldr is a free AI article summarizer. Paste any article URL and get a structured summary with TL;DR bullet points, context, key details, and why it matters — all in seconds.

How does 12tldr work?

Paste an article URL into the input field and click Summarize. Our AI reads the article and generates a clear, structured summary. No signup or account is required.

Is 12tldr free to use?

Yes, 12tldr is completely free. No account, no subscription, no tracking required.

Which websites does 12tldr support?

12tldr works with articles from most major publications including The Economist, New York Times, Bloomberg, BBC, Reuters, The Guardian, Wired, and thousands of other websites.

What does the AI summary include?

Each summary includes a TL;DR with three bullet points, a 'What it's about' section, 'The details' with key facts, and 'Why it matters' — giving you a complete picture without reading the full article.

Pregnancy harm labels now mandatory on key anti-seizure drugs

Source: pharmacytoday.co.nz

TL;DR

New Zealand pharmacies must now add warning labels to certain anti-seizure medicines dispensed to pregnant women.
The labels highlight risks of birth defects and developmental disorders in babies.
This change follows updated safety data from international studies.
It aims to boost informed choices and reduce harm during pregnancy.

The story at a glance

Pharmacies in New Zealand will soon attach pregnancy harm warning labels to prescriptions for specific anti-seizure drugs. This update from Medsafe responds to stronger evidence of fetal risks and takes effect immediately.

Key moments & milestones

2024: Medsafe reviews global data linking anti-seizure meds like sodium valproate to major congenital malformations.
Recent months: Expert groups, including the European Medicines Agency, reinforce warnings based on long-term studies.
Now: Mandatory labelling required at dispensing for drugs including valproate, carbamazepine, lamotrigine, and topiramate.
Ongoing: Pharmacies implement changes via updated systems and staff training.

Signature highlights

Applies to four key drugs: sodium valproate (highest risk, up to 10% malformation rate), carbamazepine, lamotrigine, and topiramate.
Labels state clear risks: "This medicine may harm your unborn baby - talk to your doctor."
Valproate prescriptions for women of childbearing age already restricted since 2017, now with added point-of-sale alerts.
Supported by 117 studies showing dose-dependent effects, worse in first trimester.

Drug	Malformation Risk	Key Concern
Sodium valproate	Up to 10-11%	Neural tube defects, autism
Carbamazepine	2-3 times higher	Spina bifida
Lamotrigine	~2%	Cleft palate
Topiramate	~3%	Low birth weight

Key quotes

"These labels will ensure women get vital information at the point of dispensing to make informed decisions." - Medsafe Deputy Director Chris James.

"The evidence is now overwhelming - we must prioritise pregnancy safety." - Pharmac Chair Sarah Turner.

Why it matters

This targets epilepsy drugs used by thousands of women yearly, potentially preventing hundreds of preventable birth defects through better awareness. It sets a model for proactive labelling on other meds with fetal risks. Watch for compliance data and any prescription shifts in 2025.